tetano
Editor, Senior Moderator
J Emerg Med
. 2021 Mar 26;S0736-4679(21)00305-X.
doi: 10.1016/j.jemermed.2021.03.022. Online ahead of print.
Guillain-Barré Syndrome after Novel Coronavirus Disease 2019
Jordan Yakoby[SUP] 1 [/SUP], Ilya Litvak[SUP] 2 [/SUP], Edward Yu[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Novel coronavirus disease 2019 (COVID-19) has affected more than 89 million people worldwide. As the pandemic rages on, more complications of the disease are being recognized, including stroke, cardiovascular disease, thromboembolic events, encephalopathy, seizures, and more. Peripheral nervous system involvement, particularly Guillain-Barré syndrome (GBS), is of special interest, given the increasing reports of cases related to COVID-19. Because of the potentially delayed onset of symptoms of polyradiculoneuropathy and weakness after the traditional COVID-19 symptoms, it is vitally important for emergency physicians to be vigilant and to consider GBS as part of their differential diagnosis. GBS usually occurs after an infectious insult, and a variety of culprit pathogens have been identified in the literature.
Case report: We describe the case of a 35-year-old man who developed GBS after being diagnosed with COVID-19 infection. The patient displayed classic symptoms of neuropathy, areflexia, and lower extremity weakness. Cerebrospinal fluid evaluation demonstrated albuminocytologic dissociation seen in GBS, although anti-ganglioside autoantibodies were negative. These antibodies are often negative and do not exclude the diagnosis. The patient responded clinically to intravenous immunoglobulin therapy and was discharged home. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This case report contributes further evidence that COVID-19 joins other organisms as causes of GBS. Emergency physicians are the first point of contact for many patients. Increased awareness of this complication of COVID-19 will lead to higher detection. Prompt recognition could lead to speedier and more complete neurologic recovery of affected patients.
Keywords: COVID-19; Guillain-Barre syndrome; SARS-CoV; SARS-CoV-2; anti-ganglioside autoantibodies.
. 2021 Mar 26;S0736-4679(21)00305-X.
doi: 10.1016/j.jemermed.2021.03.022. Online ahead of print.
Guillain-Barré Syndrome after Novel Coronavirus Disease 2019
Jordan Yakoby[SUP] 1 [/SUP], Ilya Litvak[SUP] 2 [/SUP], Edward Yu[SUP] 3 [/SUP]
Affiliations
- PMID: 34103203
- DOI: 10.1016/j.jemermed.2021.03.022
Abstract
Background: Novel coronavirus disease 2019 (COVID-19) has affected more than 89 million people worldwide. As the pandemic rages on, more complications of the disease are being recognized, including stroke, cardiovascular disease, thromboembolic events, encephalopathy, seizures, and more. Peripheral nervous system involvement, particularly Guillain-Barré syndrome (GBS), is of special interest, given the increasing reports of cases related to COVID-19. Because of the potentially delayed onset of symptoms of polyradiculoneuropathy and weakness after the traditional COVID-19 symptoms, it is vitally important for emergency physicians to be vigilant and to consider GBS as part of their differential diagnosis. GBS usually occurs after an infectious insult, and a variety of culprit pathogens have been identified in the literature.
Case report: We describe the case of a 35-year-old man who developed GBS after being diagnosed with COVID-19 infection. The patient displayed classic symptoms of neuropathy, areflexia, and lower extremity weakness. Cerebrospinal fluid evaluation demonstrated albuminocytologic dissociation seen in GBS, although anti-ganglioside autoantibodies were negative. These antibodies are often negative and do not exclude the diagnosis. The patient responded clinically to intravenous immunoglobulin therapy and was discharged home. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This case report contributes further evidence that COVID-19 joins other organisms as causes of GBS. Emergency physicians are the first point of contact for many patients. Increased awareness of this complication of COVID-19 will lead to higher detection. Prompt recognition could lead to speedier and more complete neurologic recovery of affected patients.
Keywords: COVID-19; Guillain-Barre syndrome; SARS-CoV; SARS-CoV-2; anti-ganglioside autoantibodies.